A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT0 个研究点目标入组 240 人开始时间: 2021年5月24日最近更新: 2021年8月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 240

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Participants are eligible to be included in the study only if all of the following criteria apply:
•1. Participant must be =18 years old, must be able to understand the study procedures, and agrees to participate in the study by providing written informed consent (as described in Appendix 4 of protocol), which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
•2. Participant has histologically- or cytologically-confirmed metastatic non-squamous NSCLC with documented absence of a sensitizing EGFR, ALK, ROS-1, or BRAF V600E mutation or other genomic aberration for which an approved targeted therapy is available.. Mixed tumors will be categorized by the predominant cell type; if the tumor has predominantly squamous cell histology or if small cell elements are present, the
•participant is ineligible.
•3. Participants must have measurable disease, ie presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment.
•Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible. See Appendix 1 of protocol for the definition of a measurable lesion.
•4. Participant has documented PD-L1 status by the 22C3 pharmDx assay (Agilent/Dako). If no prior PD-L1 result is available at the time of Screening, the participant can be tested locally using the stated method, or central PD-L1 testing can be completed. Results are needed for stratification and must be available prior to randomization.
•5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
•6. Participant has a life expectancy of at least 3 months.
•7. Participant has adequate organ function as defined in Table 5 of protocol. (Note: A complete blood count test should be obtained without transfusion or receipt of colony-stimulating factors within 2 weeks of obtaining the sample.)
•8. Participant has recovered to Grade =1 from any prior treatment-related toxicities at the time of randomization. A participant with Grade 2 alopecia is an exception to this criterion and may qualify for this study.
•9. Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 180 days after the last dose of study treatment: . (Note: duration of contraceptive use after last dose of chemotherapy must be consistent with local requirements and local approved product labels; however, the minimum duration is 180 days after last dose of chemotherapy)
•Please refer to the protocol for the complete list
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 120
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 120

排除标准

•Participants are excluded from the study if any of the following criteria apply:
•1. Participant has received prior systemic therapy for the treatment of metastatic NSCLC. Participants who have received neoadjuvant or adjuvant chemotherapy are eligible if the neoadjuvant/adjuvant therapy was completed at least 12 months prior to the development
•of metastatic disease.
•2. Participant has received prior therapy with a PD-(L)1 or PD-L2 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, or any other immunotherapy agent (eg, OX40) for the treatment of cancer.
•3. Participant has received radiation to the lung that is >30 Gy within 6 months of the first dose of study treatment.
•4. Participant has completed palliative radiotherapy within 7 days of the first dose of study treatment.
•5. Participant is ineligible if any of the following hepatic characteristics are present:
•a. ALT >2.5×upper limit of normal (ULN) without liver metastases/tumor infiltration
•b. ALT >5×ULN with liver metastases/tumor infiltration
•c. Bilirubin >1.5×ULN (isolated bilirubin >1.5×ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)
•d. Current active liver or biliary disease (with the exception of Gilbert’s syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per Investigator assessment)
•Note: Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
•6. Participant has a corrected QT interval (QTc) >450 msec (or QTc >480 msec for participants with bundle branch block).
•The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Fridericia’s formula (QTcF), and/or another method, machine-read or manually over-read.
•The specific formula that will be used to determine eligibility and discontinuation for an individual participant should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual participant and then the lowest QTc value used to include or discontinue the participant from the study.
•For purposes of data analysis, QTcB, QTcF, another QT correction formula, or a composite of available values of QTc will be used as specified in the Reporting and Analysis Plan (RAP).
•7. Participant has had major surgery within 3 weeks of the first dose of study treatment or has not adequately recovered from any AEs (Grade =1) and/or complications from any major surgery. Surgical implantation of a port catheter is not exclusionary.
•8. Participant has an additional malignancy or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
•9. Participant has known active brain metastases and/or leptomeningeal metastases. Participants who have received prior therapy for their brain metastases and have radiographically stable central nervous system disease may participate, provided they are neurologically stable for at least 2 weeks before study entry and must be off corticosteroids within 3 days prior to the first dose of study treatment. Stable brain metastases by this definition should be esta

研究者

发起方

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT

相似试验

招募中

1 期

Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non squamous Non small Cell Lung CancerMetastatic non-squamous non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-002327-11-FRGlaxoSmithKline Research & Development Ltd243

招募中

1 期

TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLAung Cancer, Non-Small CellMedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864

CTIS2023-505894-33-00Glaxosmithkline Research & Development Limited242

进行中（未招募）

1 期

EUCTR2020-002327-11-ROGlaxoSmithKline Research & Development Ltd240

进行中（未招募）

1 期

Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non squamous Non small Cell Lung Cancer

EUCTR2020-002327-11-DEGlaxoSmithKline Research & Development Ltd243

已完成

不适用

A RANDOMIZED, DOUBLE-BLIND PHASE 2B STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A 623 ADMINISTRATION IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

PER-059-10Anthera Pharmaceuticals, Inc.,55